Strides Pharma Science Ltd

Strides Pharma Science Business Update

Strides Pharma Science received a Form 483 with three observations following a routine USFDA inspection at its Alathur formulations facility. The company will respond within stipulated timelines.

Strides Pharma Science Earnings Call Transcript: Key Takeaways

Strides Pharma Science reported Q1 FY27 results with 13% YoY revenue growth and EBITDA margins maintained at 18.2%. Strategy focuses on Ex-US growth and US portfolio diversification.

Call

Guides 32% growth

Strides Pharma Science Investor Presentation: Key Takeaways

Strides Q1FY27 revenue grew 13% YoY to ₹12,654m, led by a 17% surge in Ex-US markets. Operational PAT stood at ₹1,231m.

Strides Pharma Science Q1 FY27 Results: Net Profit ₹165.5 Cr, Up 56.7% YoY

Strides Pharma Science Ltd reported revenue from operations of ₹1,265 Cr (+13.0% YoY) and net profit of ₹165.5 Cr (+56.7% YoY) for Q1 FY27.

Key figure

Net profit ₹165.5 Cr · +56.7% YoY

Strides Pharma Science Earnings Call: Key Takeaways

Strides Pharma reported its highest ever EBITDA and operational PAT for FY26, driven by significant geographical diversification and a structural shift toward non-U.S. markets.

Strides Pharma Science Earnings Call: Key Takeaways

Strides delivered strong FY26 performance with Revenue at ₹48,587m, up 6.4%, and Operational PAT at ₹5,181m, growing 50% YoY driven by Ex-US market efficiency.

Strides Pharma Science Q4 FY26 Results: Net Profit ₹129.3 Cr, Up 51.1% YoY

Strides Pharma Science Ltd reported revenue from operations of ₹1,324 Cr (+11.2% YoY) and net profit of ₹129.3 Cr (+51.1% YoY) for Q4 FY26.

Key figure

Net profit ₹129.3 Cr · +51.1% YoY